Basket trials and the evolution of clinical trial design in an era of genomic medicine

Journal of Clinical Oncology

Volumn 33, Issue 9, 2015, Pages 975-977

  Redig, Amanda J ^a   Jänne, Pasi A ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; DOCETAXEL; ERLOTINIB; LAPATINIB; SELUMETINIB; SUNITINIB; TUMOR MARKER;

ADVANCED CANCER; CANCER GENETICS; CANCER INCIDENCE; CANCER SCREENING; CLINICAL TRIAL (TOPIC); EDITORIAL; GENE MUTATION; GENOMICS; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOLID TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; LUNG NEOPLASMS; MALE; METABOLISM; SMALL CELL LUNG CARCINOMA; THYMUS NEOPLASMS;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; SMALL CELL LUNG CARCINOMA; THYMUS NEOPLASMS;

EID: 84927154472     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.8433     Document Type: Editorial

References (19)

1. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
2. Hallberg B, Palmer RH: Crizotinib: Latest champion in the cancer wars? N Engl J Med 363:1760-1762, 2010
3. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Non-small cell lung cancer (version 3.2015). http://www.nccn.org/ professionals/physician-gls/recently-updated.asp
4. Korpanty GJ, Graham DM, Vincent MD, et al: Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol 4:204, 2014
5. Ricciardi GR, Russo A, Franchina T, et al: NSCLC and HER2: Between lights and shadows. J Thorac Oncol 9:1750-1762, 2014
6. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
7. Tiacci E, Trifonov V, Schiavoni G, et al: BRAF mutations in hairy-cell leukemia. N Engl J Med 364:2305-2315, 2011
8. Prahallad A, Sun C, Huang S, et al: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483:100-103, 2012
9. Marchetti A, Felicioni L, Malatesta S, et al: Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 29:3574-3579, 2011
10. Xing M, Alzahrani AS, Carson KA, et al: Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 33:42-50, 2015
11. Berghoff AS, Preusser M: BRAF alterations in brain tumours: Molecular pathology and therapeutic opportunities. Curr Opin Neurol 27:689-696, 2014
12. Niho S, Kubota K, Goto K, et al: First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 24:64-69, 2006
13. Crinò L, Cappuzzo F, Zatloukal P, et al: Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): A randomized, phase II study. J Clin Oncol 26:4253-4260, 2008
14. Wagle N, Grabiner BC, Van Allen EM, et al: Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 4:546-553, 2014
15. Wagle N, Grabiner BC, Van Allen EM, et al: Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med 371:1426-1433, 2014
16. Lopez-Chavez A, Thomas A, Rajan A, et al: Molecular profiling and targeted therapy for advanced thoracic malignancies: A biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol 33:1000-1007, 2015
17. National Cancer Institute: Molecular Analysis for Therapy Choice (NCIMATCH). http://deainfo.nci.nih.gov/advisory/ncab/164-1213/Conley.pdf
18. Jänne PA, Shaw AT, Pereira JR, et al: Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14:38-47, 2013
19. Chen Z, Cheng K, Walton Z, et al: A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483:613-617, 2012